"The study demonstrates that medical treatment with teprotumumab is effective at reversing the manifestations of disease, providing new hope for patients," said the study's principal investigator, Raymond Douglas, MD, Ph.D., director of the Orbital and Thyroid Eye Disease Program at Cedars-Sinai.